Cenix BioScience Signs Research Service Agreement with Bayer Pharma AG
News May 06, 2014
Cenix BioScience GmbH (Cenix) has announced that is has signed a research service agreement with Bayer Pharma AG (Bayer).
Under the agreement, Cenix will undertake a target discovery project for an undisclosed disease indication by applying its longstanding industry-leading expertise in high throughput RNAi for genome-scale screening in advanced cell models.
Financial terms were not disclosed.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE